explore -WSS

explore

author：explore 2025-09-14 14:48:27 - browse：599

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Gene editing the human germline: What are the risks?

WSS

Leading voice in opioid treatment defends methadone clinic system

Colonoscopy at 40? Study finds a possible benefit

Neuroscience’s long legacy of racism

Do masks work? RCTs can't tell us

STAT's guide to the next generation of CAR

The story of mRNA: From a loose idea to a tool that may help curb Covid

knowledge

explore

leisure time

Drug repurposing or repositioning? The language matters

Baby aspirin cuts fat buildup in liver disease patients, in small study

Medicare proposal to cover medical devices draws a mixed reaction

SCOTUS questions limit to govt efforts to fight misinformation

State Dept. review finds Biden bears some blame for Afghanistan failures

Health AI adoption puts security, privacy startups on investors' radar

Moonlake's readout produced a cash windfall. Risks remain

Neuroscience’s long legacy of racism

Tori Bowie and the unacceptable rates of Black maternal death

UnitedHealth increases loan offers after Change Healthcare outage

entertainment

Neuroscience’s long legacy of racism

3 hurdles to bringing medical devices to the U.S. market

App could help diagnose ear infections more accurately — and at home

Ask STAT: What do you want to know about ChatGPT in medicine?

SCOTUS questions limit to govt efforts to fight misinformation

Creating egg and sperm cells from stem cells raises ethical issues

leisure time

entertainment

knowledge

focus